VEGF receptor kinase inhibitors: phthalazines, anthranilamides and related structures

Bibliography

• KIM KJ, LI B, WINER J et al.: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature (1993) 362:841–844.
   PubMed Web of Science ®Google Scholar
• MILLAUER B, LONGHI MP, PLATE KH et al.: Dominant-negative inhibition of flk-1 suppresses the growth of many tumor types in vivo. Cancer Res. (1996) 56:1615–1620.
   PubMed Web of Science ®Google Scholar
• BOYER SJ: Small molecule inhibitors of KDR (VEGFR-2 kinase): an overview of structure-activity relationships. Curr. Topics Med. Chem. (2002) 2:973–1000.
   PubMedGoogle Scholar
• BILODEAU MT, FRALEY ME, HARTMAN GD: Kinase insert domain-containing receptor kinase inhibitors and anti-angiogenic agents. Expert Opin. Investig Drugs (2002) 11(6):737–745.
   PubMedGoogle Scholar
• MANLEY PW, MARTINI-BARON G, SCHLAEPPI JM, WOOD JM: Therapies directed at vascular endothelial growth factor. Expert Opin. Investig. Drugs (2002) 11(12):1715–1736.
   PubMed Web of Science ®Google Scholar
• DREVS J: PTK/ZK. IDrugs (2003) 6(8):787–794.
   Google Scholar
• BOLD G, FREI J, FURET P et al.: CGP 79787D (PTK787/ZK222584), CGP 84738, NVP-AAC789, NVP-AAD777 and related phthalazines as inhibitors of VEGF-and bFGF-induced angiogenesis. Drugs Fut. (2002) 27(1):43–55.
   Google Scholar
• THOMAS AL, MORGAN B, DREVS J et al.: Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK222584. Semin. Oncol (2003) 30(3, Suppl. 0:32–38.
   Google Scholar
• BOLD G, ALTMANN KH, FREI J et al.: New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis. J. Med. Chem. (2000) 43:2310–2323.
   PubMed Web of Science ®Google Scholar
• •• Synthesis and SAR of the phthalazinePTK787.
   Google Scholar
• WOOD JM, BOLD G, BUCHDUNGER E et al.: PTK787/ ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. (2000) 60:2178–2189.
   PubMed Web of Science ®Google Scholar
• •• Pharmacological characterisation ofPTK787.
   Google Scholar
• MORGAN B, THOMAS AL, DREVS J et al.: Dynamic contrast-enhanced magnetic nuclear resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two Phase I studies. J. Clin. Oncol (2003) 21(21):3955–3964.
   PubMed Web of Science ®Google Scholar
• STEWARD WP, THOMAS B, MORGAN B et al.: Expanded Phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with FOLFOX-4 as first-line treatment for patients with metastatic colorectal cancer. J. Clin. Oncol (2004) 22(14S Suppl.):3556.
   Google Scholar
• SCHLEUCHER N, TRARBACH U, JUNKER U et al.: Phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor in combination with FOLFIRI as first-line treatment for patients with metastatic colorectal cancer. J. Clin. Oncol (2004) 22 (Supp1.145):3558.
   Google Scholar
• CONNELL RD: A case study of the gefitinib patent estate. Expert Opin. Ther. Patents (2004) 14(12):1763–1771.
   Web of Science ®Google Scholar
• • Interesting perspective on franchise protection in oncology.
   Google Scholar
• KIM LS, HUANG S, LU W, CHELOUCHE LD, PRICE JE: Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice. Clin. Exp. Metastasis (2004) 21(2):107–118.
   PubMedGoogle Scholar
• XU L, YONEDA J, HERRERA C, WOOD J, KILLION JJ, FIDLER IJ: Inhibition of malignant ascites and growth of ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int. J. Oncol (2000) 16(3):445–454.
   PubMed Web of Science ®Google Scholar
• SOLORZANO CC, BAKER CH, BRUNS CJ et al.: Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK787/ ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother. Radiopharm. (2001) 16(5):359–370.
   PubMed Web of Science ®Google Scholar
• DREVS J, HOFMANN I, HUNGENSCMIDT H et al.: Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res. (2000) 60:4819–4824.
   PubMed Web of Science ®Google Scholar
• YANO S, HERBST RS, SHINOHARA H et al.: Treatment of malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin. Cancer Res. (2000) 6:957–965.
   PubMed Web of Science ®Google Scholar
• LIN B, PODAR K, GUPTA D et al.: The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res. (2002) 62:5019–5026.
   PubMed Web of Science ®Google Scholar
• HESS C, VUONG V HEGYI I et al.: Effect of VEGF receptor inhibitor PTK787/ ZK222584 combined with ionizing radiation on endothelial cells and tumor growth. Br. J. Cancer (2001) 85(12):2010–2016.
   Google Scholar
• QIAN DZ, WANG X, KACHLAP SK et al.: The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res. (2004) 64:6626–6634.
   PubMed Web of Science ®Google Scholar
• BAKER CH, SOLORZANO CC, FIDLER IJ: Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res. (2002) 62:1996–2003.
   PubMed Web of Science ®Google Scholar
• MANLEY PW, BLUM W, BOLD G et al.:NVP -ADD777 I ZK202664, a selective VEGF receptor kinase inhibitor, which inhibits both VEGF- and bEGF-induced angiogenesis. Proceedings of the 02'd Meeting of the American Association of Cancer Research. New Orleans, USA (2001) Abstract 5052.
   Google Scholar
• TILLE JC, WOOD J, MANDRIOTA SJ et al.: Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro. Pharm. Exp. Ther. (2001) 299(3):1073–1085.
   PubMedGoogle Scholar
• ELTING J, JONES R, CORTES Get al.:BAY 57–9352 - an inhibitor of VEGFR-2 and PDGFR receptor tyrosine kinases that demonstrates anti-angiogenic activity in vitro and in vivo. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Geneva, Switzerland (2004) Abstract 139.
   Google Scholar
• • First release of the structure of BAY 57–9352.
   Google Scholar
• CHANG Y, CORTES C, BRINK C et al.:BAY 57–9352 - an inhibitor of VEGFR-2 and PDGFR receptor tyrosine kinases that demonstrates anti-tumor activity as a single agent in preclinical models. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Geneva, Switzerland (2004) Abstract 148.
   Google Scholar
• WALLE S, RADTKE M, KERN A, SCHMEER K, SEIDEL D, ADAMS P: In vitro metabolism of BAY 57–9352 - a novel VEGFR-2/PDGFR kinase inhibitor. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Geneva, Switzerland (2004) Abstract 176.
   Google Scholar
• MANLEY PW, BOLD G, BRUEGGEN J et al.: Advances in the structural biology, design and clinical development of VEGFR inhibitors for the treatment of angiogenesis. Biochem. Biophys. Acta (2004) 1697:17–27.
   PubMed Web of Science ®Google Scholar
• FURET P, BOLD G, HOFMANN F, MANLEY P, MEYER T, ALTMANN KH: Identification of a new class of potent angiogenesis inhibitors based on conformational considerations and database searching. Bioorg Med. Chem. Lett. (2003) 13:2967–2971.
   PubMed Web of Science ®Google Scholar
• •• Fine example of lead expansion using a structure-based design approach.
   Google Scholar
• MANLEY PW, FURET P, BOLD G et al.: Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J. Med. Chem. (2002) 45:5687–5693.
   PubMed Web of Science ®Google Scholar
• • Synthesis and SAR of the anthranilamide class.
   Google Scholar
• MANLEY P, BOLD G, BRUGGEN Jet al.: AAL993 (ZK260255): a member of the novel, anthranilic acid amide class of anti-angiogenic VEGF receptor kinase inhibitors. Proceedings of the 04th Meeting of the American Association of Cancer Research Washington DC (2003) Abstract 4697.
   Google Scholar
• BRUEGGEN J, BOLD G, COZENS R et al.: Preclinical profile of ABP309, a potent 2nd generation VEGFR receptor tyrosine kinase inhibitor belonging to the class of aminonicotinamides. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Geneva, Switzerland (2004) Abstract 172.
   Google Scholar
• MANLEY P, BOLD G, BRUGGEN Jet al.: Anthranilic acid derivatives: VEGF-R kinase inhibitors for anti-angiogenic therapy in cancer. 18th International Symposium on Medicinal Chemistry. Copenhagen, Denmark and Malmo, Sweden (2004) Abstract L31.
   Google Scholar
• GARTON AJ, ROSENFELD-FRANKLIN M, WINSKI SL et ell.: Identification of a series of 2,3-substituted thiophenes as inhibitors of Kit, KDR and PDGFR tyrosine kinases with anti-tumor activity. Proceedings of the 05th Meeting of the American Association of Cancer Research. Orlando, USA (2004) Abstract 3986.
   Google Scholar
• WINSKI SL, BITTNER MA, BRINER P et al.: Antitumor activity in preclinical xenograft models of OSI-930, a novel selective tyrosine kinase inhibitor. 16h EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Geneva, Switzerland (2004) Abstract 239.
   Google Scholar
• GARTON A, KAHLER J, CASTALDO L et al.: Pharmacokinetic/pharmacodynamic analysis of OSI-930, a novel selective tyrosine inhibitor with anti-tumor activity. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Geneva, Switzerland (2004) Abstract 413.
   Google Scholar
• OSI PHARMACEUTICALS: OSI Pharmaceuticals begins clinical development in c-kit / VEGFR program - lead candidate OSI-930 advances to phase I clinical trial. Company Press Release, February 28,2005.
   Google Scholar
• NO AUTHORS LISTED: Substituted alkylamines and methods of use. Expert Opin. Ther. Patents (2002) 12(12):1909–1914.
   Google Scholar
• HECHT JR, TRARBACH T, JAEGER E et al.: A randomized, double-blind, placebo controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/ 5-fluorouracil/leucovorin and PTK787/ ZK222584 or placebo (CONFIRM-1). 41st Meeting of Am. Assoc. Clin. Oncol., Orlando, FL (2005) Abstract LB3.
   Google Scholar